title: [Prognostic analysis of 349 cases with gastrointestinal stromal tumor].
abstract: OBJECTIVE
  To investigate the prognostic factors of gastrointestinal stromal tumor (GIST).
  
  
  METHODS
  Clinical data of 349 cases of GIST patients in our hospital between January 2006 and September 2011 were analyzed retrospectively and the prognostic factors were evaluated.
  
  
  RESULTS
  335 patients underwent R0 resection and 14 with palliative resection. With a follow-up of 288 (82.5%) patients (median: 33 months, range 3-72 months), 61 patients with progressed were observed and 33 of them died. Unconditional logistic regression analysis showed that tumor location (P = 0.003, OR = 1.412, 95% CI: 1.125-1.772), risk classification (P = 0.011, OR = 2.930, 95% CI: 1.278-6.716) and use of imatinib treatment (P = 0.009, OR =0.291, 95 CI: 0.115-0.734) were independent factors for post-operative recurrence or metastasis. Survival analysis of 128 patients between January 2006 and December 2008, Cox regression analysis demonstrated diameter (P = 0.034, OR = 2.328, 95% CI: 1.065-5.089), risk classification (P = 0.015, OR = 3.031, 95% CI: 1.236-7.428) and use of imatinib treatment (P = 0.011, OR = 0.259, 95% CI: 0.091-0.734) were independent prognosis factors.
  
  
  CONCLUSIONS
  No specific clinical manifestation was observed for GIST. Tumor location, diameter, risk classification and imatinib treatment could influence on prognosis. Radical resection combined with imatinib treatment could improve the prognosis.
authors.affiliation: Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Hong-Xin
authors.initials: HX
authors.lastname: Yang
authors.forename: Hai-Ning
authors.initials: HN
authors.lastname: Chen
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Chao-Yong
authors.initials: CY
authors.lastname: Shen
authors.forename: Zhi-Xin
authors.initials: ZX
authors.lastname: Chen
authors.forename: Jia-Ping
authors.initials: JP
authors.lastname: Chen
mesh_terms: D001549:Benzamides / Q000627:therapeutic use; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000401:mortality; D006801:Humans; D000068877:Imatinib Mesylate; D009364:Neoplasm Recurrence, Local; D010879:Piperazines / Q000627:therapeutic use; D011184:Postoperative Period; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate